Omics-based Clinical Trials Market Report Scope & Overview:
The omics-based clinical trials market size was valued at USD 32.75 billion in 2024 and is expected to reach USD 61.98 billion by 2032, growing at a CAGR of 8.36% over the forecast period of 2025-2032.
The global omics-based clinical trials market is experiencing strong growth due to the disruptive nature of genomics, proteomics, metabolomics, and transcriptomics on drug development and precision medicine. Acceptance is being driven by the growing need for tailor-made treatments, next-generation sequencing technology, and the availability of multiple AI-driven data analytics. Over the years, the pharmaceutical and biotechnological companies have been relying extensively upon omics insights for precise stratification of patients and to improve the chances of success of their trials.
The U.S. omics-based clinical trials market size was valued at USD 9.37 billion in 2024 and is expected to reach USD 17.43 billion by 2032, growing at a CAGR of 8.11% over the forecast period of 2025-2032.
North America's omics-based clinical trials market has been dominated by the U.S. due to the large research infrastructure, presence of Pharmaceutical and Biotech companies, and the high clinical trial activity in the country. It is backed by favorable regulatory support and major R&D investments, further fortifying its leadership within the region.
Market Dynamics:
Drivers
- Increasing Demand for RNA-Based Therapeutics and Vaccines is Expected to Drive the Growth of the Omics-based Clinical Trials Market
The growing number of research studies on circRNA therapeutics and vaccines is a key factor driving the growth of the circRNA synthesis market. Existing mRNA vaccines, such as those against COVID-19, reaffirm the promise of these RNA platforms against infectious diseases. On the other hand, circRNAs are advantageous over linear RNAs as they are more stable, less degradable by exo-nucleases, and provide sustained protein expression compared to linear RNA species. This design makes them appealing to be used in the next generation of vaccines, gene therapy, and rare disease therapies. Several pharmaceutical and biotechnology companies are investing substantial resources to understand and develop therapeutics based on circRNA, which is creating an urgent need for advanced circRNA synthesis technologies and services.
According to the Personalized Medicine Coalition, the number of personalized medicines in the U.S. more than doubled from 132 in 2016 to 286 in 2020, and personalized therapies represented 25% of new FDA drug approvals in 2019, an increase from just 5% 2005
An Applied Clinical Trials review highlights that multi-omics data—which integrate genomics, transcriptomics, and proteomics—are critical for elucidating disease biology and optimizing treatment response as precision medicine advances in practice.
- Investments in Biotech and Genomic Research on the Rise are Fueling the Market
The growing wave of investment that has been seen across the public and private sectors in providing funding for biotechnological and genomic research is driving the omics-based clinical trials market growth. Governments and research institutes alike, and venture capitalists, are betting big on RNA-based innovation, and circRNA is emerging as an attractive new class of molecules with far-reaching potential in diagnostics, therapeutics, and personalized medicine. CircRNAs have recently gained attention as potential biomarkers for cancer and other complex diseases, and are being researched heavily and their potential. (Science Direct) Such an increase in capital inflow from both regions facilitates the building of advanced synthesis platforms, scalable production capacities, and stronger biotech-academia collaborations, which in turn are aiding the market growth of circRNA synthesis.
Roche recently launched its new Sequencing by Expansion (SBX) technology, increasing speed and scalability in next-generation sequencing, which has the capability of powering big omics (genomic, transcriptomic, and epigenomic data across multiple domains) studies in clinical research.
Spatial biology is foreseen as an emerging discipline by the industry starting from 2025, aided by breakthroughs in high-throughput sequencing technologies that allow large, affordable-scale analyses of tissue microenvironments essential for both translational and clinical uses.
BRB-seq, an ultra-high-throughput RNA sequencing technology employing early-stage sample barcoding, provides a cost reduction of up to 25-fold relative to standard RNA-seq, thus accelerating transcriptomic characterization in patient studies.
Restraint
- Expensive Omics Technologies Hamper the Growth of the Omics-Based Clinical Trials Market, Thus Limiting Their Wide Adoption
High capital expenditures for omics technologies such as genomics, metabolonomics, or proteomics render large numbers of samples financially impractical for many research facilities and clinical environments, posing a serious barrier. Moreover, the validation of data from multi-omics platforms presents a complex landscape of integration and interpretation where the need for specialized bioinformatics tools can create skill gaps and operational challenges. Regulatory roadblocks, such as strict protocols associated with privacy, the ethical use of omics data, and the standardization of relevant methodology, delay trial approvals. In addition, a clear infrastructure gap and lack of clarity on reimbursement policies in many developing regions are further challenges in making omics-driven clinical trials globally accessible and scalable.
Segmentation Analysis:
By Phase
The phase III segment dominated the omics-based clinical trials market share in 2024 with 52.4%, as it is the resource-intensive and large-scale stage of clinical development. During the validation stage, omics technologies are critical for validating biomarkers, stratifying patient populations, and characterizing safety and efficacy in different populations. For new therapies, approval by glonal regulatory authorities is such a high-stakes bet that Phase III trials command the highest proportions of clinical R&D costs and resources.
The Phase I segment is anticipated to experience the highest growth in the forecast years, owing to the rising adoption of omics-based approaches in early phase trials for patient selection due to biomarker discovery. The increasing focus on precision medicine, personalized treatments, and lowering clinical trial attrition rates promotes the adoption of genomics/transcriptomics/proteomics earlier in development. The early utilization of omics in phase I aids in making faster decisions and improving trial efficiency, which prepares the ground for the tertiary phase-driven rapid growth.
By Study Design
The omics-based clinical trials market for the interventional studies segment held the largest share in 2024, with 42.15%, as these trials are crafted to evaluate new therapies directly, often informed by omics-driven insights, evaluating their safety, efficacy, and outcomes. Genomics, proteomics, and transcriptomics have major contributions to interventional studies as these tools are used to identify biomarkers, to aid with patient population stratification, and to assist with therapeutic stratification. Due to these trials are mostly used by pharmaceutical and biotech companies for drug development, regulatory approvals, and precision medicine strategies, most of the resources go into interventional trials, perpetuating a cycle of continued dominance for interventional trials.
The fastest growth segment of the omics-based clinical trials market will be the observational studies segment, owing to the growing significance of real-world evidence and longitudinal patient data. These types of observational, omics-based research allow for the tracking of disease, treatment outcomes, and biological marker transitions in real-world scenarios alongside clinical trial data. The expanding availability of clinical and genomic data, due to the increasing adoption of electronic health records (EHRs), population-based genomic initiatives, and big data analytics, facilitates observational studies that represent an essential component of next-generation clinical research and play an important role in their rapid expansion.
By Indication
Due to the wide applications of omics technologies in both cancer research and drug development, the oncology segment held a dominant share in the omics-based clinical trials market in 2024, with a 46.18%. Oncology research has been particularly dependent on genomics, proteomics, and transcriptomics to discern predictive biomarkers, characterize tumor heterogeneity, and ultimately inform the individualization of treatment approaches. Since the global cancer burden is on the rise and the pharmaceutical companies are investing significantly in precision oncology, there is an ever-increasing need for omics-driven clinical trials predominantly in oncology, which cements the frontrunner pedestal to oncology in terms of market scope.
The autoimmune/inflammation segment is anticipated to grow significantly during the forecast period, owing to the application of omics approaches to understand the etiology of immune-mediated diseases. Recent advances in genomics, metabolomics, and proteomics are improving biomarker discovery and patient stratification in diseases including rheumatoid arthritis, lupus, and inflammatory bowel disease. The increasing incidence of autoimmune diseases, along with increased CAPEX in novel biologics and targeted therapy developments, is expected to make this segment a prominent growth lever, thereby expanding the footprint of omics-based trials.
By End User
The pharmaceutical & biotechnology companies segment accounted for the largest share of the omics-based clinical trials market in 2024 with 39.5% market share, and is expected to remain dominant in the coming years, owing to the increasing focus of these companies on drug discovery, biomarker development, and precision medicine. With funding, infrastructure, and sophisticated collaborations to scale omics technologies into large-scale clinical trials, these companies are positioned well. Their focus on biomarker-driven strategies to expedite drug development timelines, decrease trial failures, and regulatory approvals further solidifies their leadership position within this market segment.
The academic & research institutes segment is estimated to grow at the highest growth rate throughout the forecast period, driven by government funding support and joint programs with industry players. These institutions are increasingly utilizing queuing omics technologies to perform exploratory and translational research. With genomics and systems biology emerging as major areas of research at universities and other research centers, early-stage discovery efforts are being accelerated. As the momentum around innovation and foundational science continues to build, these academic institutions will emerge as key players in powering the next generation of this discipline for omics-based clinical trials.
Regional Analysis:
The global omics-based clinical trials market is dominated by North America with a 37.61% market share in 2024, owing to its advanced healthcare infrastructure, constant presence of leading pharmaceutical and biotechnology companies in the region, and investment in precision medicine research. They have strong regulatory frameworks, such as those offered by the U.S. FDA, encouraging the application of genomics, transcriptomics, proteomics, and metabolomics in the clinical trials process. Apart from it, North America has the highest number of clinical research organizations (CROs), academic research institutes, and technology providers, which drives innovation and enables faster execution of trials. Coupled with huge funding initiatives backed by government or corporates, personalized medicine will have another level of shelf from the region.
The omics-based clinical trials market trend in the Asia Pacific is anticipated to be the fastest growing, owing to the increase in clinical research activity, rapidly growing biotechnology sectors, and increasing patient enrollment capabilities in the region. The future appears to be solid for precision medicine and genomics research in countries such as China, India, South Korea, and many others, with government policies that are attractive for researchers and substantial international collaborations. It provides a price benefit to perform trials and numerous genetic populations beneficial for omics-based research. Increasing expenditures on healthcare, improving regulatory frameworks, and the acceptance of advanced technologies are also complementing growth.
Europe is the second fastest-growing region in the omics-based clinical trials market on account of investments in precision medicine, the availability of a well-established research infrastructure, and collaborative multi-stakeholder initiatives orchestrated at the level of academic institutions, biopharmaceutical companies, and regulatory authorities. Supportive European Medicines Agency (EMA) policies, growing uptake of genomics, proteomics, and metabolomics technologies, and a growing number of clinical trials on rare diseases and personalised therapies are factors contributing to the growth, the report said.
The omics-based clinical trials market analysis in Latin America and the Middle East & Africa (MEA) is expected to observe moderate growth owing to factors such as gradual cleansing of healthcare infrastructure, rising research collaborations, and capital investments in precision medicine. Low funding scenarios, regulatory constraints, and low adoption of advanced omics technologies vs. developed regions limit growth in these regions to moderate growth rather than rapid expansion.
Key Players:
Omics-based clinical trials market companies are Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratories, ICON plc, SGS SA, Eli Lilly and Company, Pfizer Inc., Covance Inc. (Labcorp Drug Development), Novo Nordisk A/S, Rebus Biosystems, Thermo Fisher Scientific, Illumina, Agilent Technologies, Qiagen, Roche, Eurofins Scientific, Siemens Healthineers, Fulgent Genetics, NeoGenomics Laboratories, Tempus Labs, and other players.
Recent Developments:
- January 2025, Parexel's newest findings outline how combining multi-omics data—involving genomics, transcriptomics, proteomics, metabolomics, epigenomics, and new spatial genomics—with the latest computational technology, such as machine learning (ML) and deep learning (DL), is revolutionizing biomarker discovery in precision oncology. The technologies allow sponsors to identify diagnostic, prognostic, and predictive biomarkers more quickly. This simplifies patient selection, enhances trial design, and enhances response prediction, ultimately allowing for quicker, more patient-focused cancer treatments
- Oct 2023, Charles River Laboratories highlights how omics-based testing technologies streamline drug discovery and minimize animal use. Through the incorporation of high-precision omics data sets—genomics, proteomics, and metabolomics—these New Approach Methodologies (NAMs) facilitate more ethical, data-enabled pipeline selection and facilitate the transition to alternatives for conventional in vivo testing.
Omics-based Clinical Trials Market Report Scope:
Report Attributes Details Market Size in 2024 USD 32.75 Billion Market Size by 2032 USD 61.98 Billion CAGR CAGR of 8.36% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook Key Segments • By Phase (Phase I, Phase II, Phase III, Phase IV)
• By Study Design (Interventional Studies, Observational Studies, Expanded Access Studies)
• By Indication (Autoimmune/Inflammation, Pain Management, Oncology, CNS Conditions, Diabetes, Obesity, Cardiovascular, Others)
• By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs), Hospitals & Clinics)Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Company Profiles Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratories, ICON plc, SGS SA, Eli Lilly and Company, Pfizer Inc., Covance Inc. (Labcorp Drug Development), Novo Nordisk A/S, Rebus Biosystems, Thermo Fisher Scientific, Illumina, Agilent Technologies, Qiagen, Roche, Eurofins Scientific, Siemens Healthineers, Fulgent Genetics, NeoGenomics Laboratories, Tempus Labs, and other players.
Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Phase
2.3.2 Market Size By Study Design
2.3.2 Market Size By Indication
2.3.2 Market Size By End User
2.4 Market Share & Bps Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Life Cycle Assessment
3.5 Parent Market Overview
3.6 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Prescription Trends by Region (2024)
4.1.1 Adoption rate of specific drug classes and therapies
4.1.2 Regional variations in prescribing behavior (North America, Europe, Asia-Pacific, etc.)
4.1.3 Influence of clinical guidelines and reimbursement policies
4.1.4 Shifts towards targeted and personalized therapies
4.2 Device Volume by Region (2020–2032)
4.2.1 Historical device utilization (2020–2023)
4.2.2 Projected device demand growth (2024–2032)
4.2.3 Regional breakdown of device adoption and penetration
4.2.4 Emerging markets driving device uptake
4.3 Healthcare Spending by Region (Government, Commercial, Private, Out-of-Pocket), 2024
4.3.1 Government healthcare expenditure patterns
4.3.2 Role of commercial and private insurance providers
4.3.3 Patient out-of-pocket spending impact
4.3.4 Regional disparities in healthcare financing
5. Omics-based Clinical Trials Market Segmental Analysis & Forecast, By Phase, 2021 – 2032, Value (USD Billion)
5.1 Introduction
5.2 Phase I
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Phase II
5.3.1 Key Trends
5.3.2 Market Size & Forecast, 2021 – 2032
5.4 Phase III
5.4.1 Key Trends
5.4.2 Market Size & Forecast, 2021 – 2032
5.5 Phase IV
5.5.1 Key Trends
5.5.2 Market Size & Forecast, 2021 – 2032
6. Omics-based Clinical Trials Market Segmental Analysis & Forecast, By Study Design, 2021 – 2032, Value (USD Billion)
6.1 Introduction
6.2 Interventional Studies
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Observational Studies
6.3.1 Key Trends
6.3.2 Market Size & Forecast, 2021 – 2032
6.4 Expanded Access Studies
6.4.1 Key Trends
6.4.2 Market Size & Forecast, 2021 – 2032
7. Omics-based Clinical Trials Market Segmental Analysis & Forecast, By Indication, 2021 – 2032, Value (USD Billion)
7.1 Introduction
7.2 Autoimmune/inflammation
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 Pain management
7.3.1 Key Trends
7.3.2 Market Size & Forecast, 2021 – 2032
7.4 Oncology
7.4.1 Key Trends
7.4.2 Market Size & Forecast, 2021 – 2032
7.5 CNS conditions
7.5.1 Key Trends
7.5.2 Market Size & Forecast, 2021 – 2032
7.6 Diabetes
7.6.1 Key Trends
7.6.2 Market Size & Forecast, 2021 – 2032
7.7 Obesity
7.7.1 Key Trends
7.7.2 Market Size & Forecast, 2021 – 2032
7.8 Cardiovascular
7.8.1 Key Trends
7.8.2 Market Size & Forecast, 2021 – 2032
7.9 Others
7.9.1 Key Trends
7.9.2 Market Size & Forecast, 2021 – 2032
8. Omics-based Clinical Trials Market Segmental Analysis & Forecast, By End User, 2021 – 2032, Value (USD Billion)
8.1 Introduction
8.2 Pharmaceutical & Biotechnology Companies
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2021 – 2032
8.3 Academic & Research Institutes
8.3.1 Key Trends
8.3.2 Market Size & Forecast, 2021 – 2032
8.4 Contract Research Organizations (CROs)
8.4.1 Key Trends
8.4.2 Market Size & Forecast, 2021 – 2032
8.5 Hospitals & Clinics
8.5.1 Key Trends
8.5.2 Market Size & Forecast, 2021 – 2032
9. Omics-based Clinical Trials Market Segmental Analysis & Forecast By Region, 2021 – 2025, Value (USD Billion)
9.1 Introduction
9.2 North America
9.2.1 Key Trends
9.2.2 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.2.3 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.2.4 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.2.5 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.2.6 Omics-based Clinical Trials Market Size & Forecast, By Country, 2021 – 2032
9.2.6.1 USA
9.2.6.1.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.2.6.1.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.2.6.1.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.2.6.1.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.2.6.2 Canada
9.2.6.2.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.2.6.2.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.2.6.2.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.2.6.2.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.3 Europe
9.3.1 Key Trends
9.3.2 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.3.3 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.3.4 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.3.5 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.3.6 Omics-based Clinical Trials Market Size & Forecast, By Country, 2021 – 2032
9.3.6.1 Germany
9.3.6.1.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.3.6.1.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.3.6.1.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.3.6.1.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.3.6.2 UK
9.3.6.2.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.3.6.2.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.3.6.2.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.3.6.2.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.3.6.3 France
9.3.6.3.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.3.6.3.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.3.6.3.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.3.6.3.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.3.6.4 Italy
9.3.6.4.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.3.6.4.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.3.6.4.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.3.6.4.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.3.6.5 Spain
9.3.6.5.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.3.6.5.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.3.6.5.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.3.6.5.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.3.6.6 Russia
9.3.6.6.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.3.6.6.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.3.6.6.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.3.6.6.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.3.6.7 Poland
9.3.6.7.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.3.6.7.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.3.6.7.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.3.6.7.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.3.6.8 Rest of Europe
9.3.6.8.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.3.6.8.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.3.6.8.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.3.6.8.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.4 Asia-Pacific
9.4.1 Key Trends
9.4.2 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.4.3 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.4.4 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.4.5 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.4.6 Omics-based Clinical Trials Market Size & Forecast, By Country, 2021 – 2032
9.4.6.1 China
9.4.6.1.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.4.6.1.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.4.6.1.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.4.6.1.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.4.6.2 India
9.4.6.2.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.4.6.2.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.4.6.2.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.4.6.2.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.4.6.3 Japan
9.4.6.3.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.4.6.3.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.4.6.3.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.4.6.3.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.4.6.4 South Korea
9.4.6.4.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.4.6.4.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.4.6.4.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.4.6.4.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.4.6.5 Australia
9.4.6.5.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.4.6.5.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.4.6.5.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.4.6.5.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.4.6.6 ASEAN Countries
9.4.6.6.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.4.6.6.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.4.6.6.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.4.6.6.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.4.6.7 Rest of Asia-Pacific
9.4.6.7.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.4.6.7.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.4.6.7.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.4.6.7.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.5 Latin America
9.5.1 Key Trends
9.5.2 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.5.3 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.5.4 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.5.5 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.5.6 Omics-based Clinical Trials Market Size & Forecast, By Country, 2021 – 2032
9.5.6.1 Brazil
9.5.6.1.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.5.6.1.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.5.6.1.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.5.6.1.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.5.6.2 Argentina
9.5.6.2.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.5.6.2.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.5.6.2.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.5.6.2.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.5.6.3 Mexico
9.5.6.3.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.5.6.3.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.5.6.3.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.5.6.3.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.5.6.4 Colombia
9.5.6.4.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.5.6.4.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.5.6.4.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.5.6.4.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.5.6.5 Rest of Latin America
9.5.6.5.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.5.6.5.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.5.6.5.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.5.6.5.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.6 Middle East & Africa
9.6.1 Key Trends
9.6.2 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.6.3 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.6.4 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.6.5 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.6.6 Omics-based Clinical Trials Market Size & Forecast, By Country, 2021 – 2032
9.6.6.1 UAE
9.6.6.1.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.6.6.1.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.6.6.1.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.6.6.1.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.6.6.2 Saudi Arabia
9.6.6.2.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.6.6.2.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.6.6.2.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.6.6.2.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.6.6.3 Qatar
9.6.6.3.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.6.6.3.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.6.6.3.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.6.6.3.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.6.6.4 Egypt
9.6.6.4.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.6.6.4.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.6.6.4.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.6.6.4.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.6.6.5 South Africa
9.6.6.5.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.6.6.5.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.6.6.5.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.6.6.5.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
9.6.6.6 Rest of Middle East & Africa
9.6.6.6.1 Omics-based Clinical Trials Market Size & Forecast, By Phase, 2021 – 2032
9.6.6.6.2 Omics-based Clinical Trials Market Size & Forecast, By Study Design, 2021 – 2032
9.6.6.6.3 Omics-based Clinical Trials Market Size & Forecast, By Indication, 2021 – 2032
9.6.6.6.4 Omics-based Clinical Trials Market Size & Forecast, By End User, 2021 – 2032
10. Competitive Landscape
10.1 Key Players' Positioning
10.2 Competitive Developments
10.2.1 Key Strategies Adopted (%), By Key Players, 2024
10.2.2 Year-Wise Strategies & Development, 2021 – 2025
10.2.3 Number Of Strategies Adopted By Key Players, 2024
10.3 Market Share Analysis, 2024
10.4 Product/Service & Application Benchmarking
10.4.1 Product/Service Specifications & Features By Key Players
10.4.2 Product/Service Heatmap By Key Players
10.4.3 Application Heatmap By Key Players
10.5 Industry Start-Up & Innovation Landscape
10.6 Key Company Profiles
10.6 Key Company Profiles
10.6.1 Parexel International Corporation
10.6.1.1 Company Overview & Snapshot
10.6.1.2 Product/Service Portfolio
10.6.1.3 Key Company Financials
10.6.1.4 SWOT Analysis
10.6.2 Pharmaceutical Product Development (PPD)
10.6.2.1 Company Overview & Snapshot
10.6.2.2 Product/Service Portfolio
10.6.2.3 Key Company Financials
10.6.2.4 SWOT Analysis
10.6.3 Charles River Laboratories
10.6.3.1 Company Overview & Snapshot
10.6.3.2 Product/Service Portfolio
10.6.3.3 Key Company Financials
10.6.3.4 SWOT Analysis
10.6.4 ICON plc
10.6.4.1 Company Overview & Snapshot
10.6.4.2 Product/Service Portfolio
10.6.4.3 Key Company Financials
10.6.4.4 SWOT Analysis
10.6.5 SGS SA
10.6.5.1 Company Overview & Snapshot
10.6.5.2 Product/Service Portfolio
10.6.5.3 Key Company Financials
10.6.5.4 SWOT Analysis
10.6.6 Eli Lilly and Company
10.6.6.1 Company Overview & Snapshot
10.6.6.2 Product/Service Portfolio
10.6.6.3 Key Company Financials
10.6.6.4 SWOT Analysis
10.6.7 Pfizer Inc.
10.6.7.1 Company Overview & Snapshot
10.6.7.2 Product/Service Portfolio
10.6.7.3 Key Company Financials
10.6.7.4 SWOT Analysis
10.6.8 Covance Inc. (Labcorp Drug Development)
10.6.8.1 Company Overview & Snapshot
10.6.8.2 Product/Service Portfolio
10.6.8.3 Key Company Financials
10.6.8.4 SWOT Analysis
10.6.9 Novo Nordisk A/S
10.6.9.1 Company Overview & Snapshot
10.6.9.2 Product/Service Portfolio
10.6.9.3 Key Company Financials
10.6.9.4 SWOT Analysis
10.6.10 Rebus Biosystems
10.6.10.1 Company Overview & Snapshot
10.6.10.2 Product/Service Portfolio
10.6.10.3 Key Company Financials
10.6.10.4 SWOT Analysis
10.6.11 Thermo Fisher Scientific
10.6.11.1 Company Overview & Snapshot
10.6.11.2 Product/Service Portfolio
10.6.11.3 Key Company Financials
10.6.11.4 SWOT Analysis
10.6.12 Illumina
10.6.12.1 Company Overview & Snapshot
10.6.12.2 Product/Service Portfolio
10.6.12.3 Key Company Financials
10.6.12.4 SWOT Analysis
10.6.13 Agilent Technologies
10.6.13.1 Company Overview & Snapshot
10.6.13.2 Product/Service Portfolio
10.6.13.3 Key Company Financials
10.6.13.4 SWOT Analysis
10.6.14 Qiagen
10.6.14.1 Company Overview & Snapshot
10.6.14.2 Product/Service Portfolio
10.6.14.3 Key Company Financials
10.6.14.4 SWOT Analysis
10.6.15 Roche
10.6.15.1 Company Overview & Snapshot
10.6.15.2 Product/Service Portfolio
10.6.15.3 Key Company Financials
10.6.15.4 SWOT Analysis
10.6.16 Eurofins Scientific
10.6.16.1 Company Overview & Snapshot
10.6.16.2 Product/Service Portfolio
10.6.16.3 Key Company Financials
10.6.16.4 SWOT Analysis
10.6.17 Siemens Healthineers
10.6.17.1 Company Overview & Snapshot
10.6.17.2 Product/Service Portfolio
10.6.17.3 Key Company Financials
10.6.17.4 SWOT Analysis
10.6.18 Fulgent Genetics
10.6.18.1 Company Overview & Snapshot
10.6.18.2 Product/Service Portfolio
10.6.18.3 Key Company Financials
10.6.18.4 SWOT Analysis
10.6.19 NeoGenomics Laboratories
10.6.19.1 Company Overview & Snapshot
10.6.19.2 Product/Service Portfolio
10.6.19.3 Key Company Financials
10.6.19.4 SWOT Analysis
10.6.20 Tempus Labs
10.6.20.1 Company Overview & Snapshot
10.6.20.2 Product/Service Portfolio
10.6.20.3 Key Company Financials
10.6.20.4 SWOT Analysis
11. Analyst Recommendations
11.1 SNS Insider Opportunity Map
11.2 Industry Low-Hanging Fruit Assessment
11.3 Market Entry & Growth Strategy
11.4 Analyst Viewpoint & Suggestions On Market Growth
12. Assumptions
13. Disclaimer
14. Appendix
14.1 List Of Tables
14.2 List Of Figures
Key Segments:
By Phase
-
- Phase I
- Phase II
- Phase III
- Phase IV
By Study Design
-
- Interventional Studies
- Observational Studies
- Expanded Access Studies
By Indication
-
- Autoimmune/inflammation
- Pain management
- Oncology
- CNS conditions
- Diabetes
- Obesity
- Cardiovascular
- Others
By End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Contract Research Organizations (CROs)
- Hospitals & Clinics
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- ASEAN Countries
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- Egypt
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g., Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
